February 16th 2022
February 15th 2022
FDA Approves Paxlovid for COVID-19 in Adults, Continues Strategy to Minimize Infection Severity
May 25th 2023This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Evaluating the Benefits and Risks of Fecal Microbiota Transplantation for Recurrent C diff
FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.
Expanding HCV Care: Effectiveness of Accessible Testing and Treatment for People Who Inject Drugs
By implementing rapid point-of-care HCV RNA testing in supervised consumption services, a study achieved high testing acceptance and successful engagement with HCV care among individuals who inject drugs.
FDA Advisory Committee Affirms Safety and Efficacy of Pfizer RSVpreF Vaccine
RSVpreF receives strong support from the FDA's VRBPAC, with positive votes for efficacy and safety. The vaccine shows promise in preventing severe respiratory illness in infants, and an FDA authorization decision is expected in August 2023.
AI-Driven Advancements Pave the Way to Test for COVID-19 and Hepatitis at Home
These new tests, conducted in a single tube within minutes, could enable at-home testing for various diseases. By incorporating CRISPR technology, the test achieves high reliability by distinguishing between false and true positives.
LMN-201 Fast Tracked by FDA as a Potential Breakthrough Treatment for C diff Infection
LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.